Drugs in ATC Class B03AB

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B03 - ANTIANEMIC PREPARATIONS

Up to B03A - IRON PREPARATIONS

Drugs in ATC Class: B03AB - Iron trivalent, oral preparations

Tradename	Generic Name
ACCRUFER	ferric maltol

B03AB Market Analysis and Financial Projection

The global market for trivalent iron oral preparations (ATC Class B03AB) is experiencing significant growth driven by rising demand for safer, more effective iron deficiency treatments, alongside a dynamic patent landscape focused on improving bioavailability and reducing side effects.

---

Market Dynamics

The IV and oral iron drugs market was valued at $7.66 billion in 2023, projected to reach $16.34 billion by 2029 (CAGR: 13.47%)[4]. Key drivers include:

• Increasing prevalence of iron deficiency anemia (IDA) linked to chronic diseases (e.g., CKD, cancer).
• Shift toward trivalent iron formulations (e.g., ferric maltol, ferric oxide polymaltose) due to lower toxicity compared to ferrous salts[3][18].
• Regulatory approvals for novel agents like ferric maltol (Accrufer), which offers improved absorption and tolerability[16].

Geographic Trends

• Baltic states: Latvia leads in B03AB utilization (2.38 DDD per 1,000 inhabitants), while Lithuania and Estonia show lower consumption[6].
• Asia-Pacific: Emerging as a production hub, with China dominating patent filings (1,654 priority applications in 2021)[2].

---

Patent Landscape

Key Innovations

1. Formulation Stability:

   • Patents cover methods to stabilize Fe³⁺ complexes with polysaccharides (e.g., maltodextrins, sucrose) to prevent oxidation and improve shelf life[3][13].
   • Example: US Patent 8,025,878B2 outlines processes for iron-carbohydrate complexes with reduced toxicity (LD₅₀ > 2,000 mg Fe/kg)[13].

2. Bioequivalence Testing:

   • Methods like T₇₅ reduction kinetics (measuring Fe³⁺ to Fe²⁺ conversion) ensure generic formulations match branded products[10].

3. Novel Delivery Systems:

   • Orodispersible films (ODFs) for rapid disintegration and taste masking[15].
   • Iron oxo-hydroxide adipate tartrate (IHAT), a low-cost, high-bioavailability alternative to traditional supplements[19].

Filing Trends

• 2010–2024: Surge in patents related to carbohydrate-iron complexes, driven by demand for non-IV alternatives[2][18].

• Priority Countries:	Country	Patent Activity (2021–2024)
  China (CN)	1,654 applications (2021)
  US (US)	Steady filings (~230 active)
  South Korea (KR)	Consistent R&D focus

---

Competitive Landscape

Leading Players

• Nemysis Limited: Licensed IHAT technology, targeting cost-effective oral iron supplements[19].
• Astron Research: Holds patents for iron-sucrose bioequivalence standards[10].
• Pharmaceutical Giants: Focus on advancing combination therapies (e.g., iron + folic acid)[11].

Challenges

• Toxicity Concerns: Traditional ferrous salts cause gastrointestinal issues, necessitating complexation strategies[18].
• Regulatory Hurdles: Strict EMA and FDA requirements for stability and bioavailability[12].

---

"The future of iron therapy lies in formulations that mimic natural dietary iron absorption while minimizing side effects." – Industry Expert[19].

---

Key Takeaways

• The B03AB market is expanding rapidly, driven by innovation in formulation stability and bioavailability.
• China dominates patent activity, reflecting its role as a manufacturing and R&D hub.
• Next-generation products like IHAT and ODFs aim to address unmet needs in patient compliance and safety.

FAQs

1. Why are trivalent iron formulations preferred?
   Lower toxicity and controlled release compared to ferrous salts[18].
2. Which countries lead in B03AB consumption?
   Latvia and South Korea show higher utilization rates[6][2].
3. What is IHAT?
   A synthetic iron supplement mimicking dietary iron absorption, with reduced side effects[19].
4. How do patents influence market entry?
   Bioequivalence standards (e.g., T₇₅ testing) ensure generics match innovator products[10].
5. What role does material science play?
   Advanced polysaccharide complexes improve stability and patient tolerance[3][13].

References

1. https://atcddd.fhi.no/atc_ddd_index/?code=B03AB&showdescription=no
2. https://www.questel.com/resourcehub/patent-landscape-analysis-shape-memory-materials/
3. https://patents.google.com/patent/US8993748B2/en
4. https://www.arizton.com/market-reports/iv-iron-oral-iron-drugs-market
5. https://www.businesswire.com/news/home/20250226537716/en/Butyl-Acetate-BAC-Global-Industry-Research-Report-2025-Regional-and-Country-Market-Analysis-2019-2024-and-Outlook-to-2034---Consumption-Capacity-Production-Trade-Prices---ResearchAndMarkets.com
6. https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/09vLW9zMlcw.pdf
7. https://atcddd.fhi.no/atc_ddd_index/?code=B03AB&showdescription=yes
8. https://www.globenewswire.com/news-release/2025/02/25/3032292/28124/en/Orthopaedic-Braces-and-Supports-Patent-Landscape-Report-2025-United-States-Leads-with-Over-550-Patents-Filed-Historically-and-230-Currently-In-Progress.html
9. https://ipwatchdog.com/2020/10/28/uspto-benchmark-study-artificial-intelligence-patent-landscape/id=126847/
10. https://patents.justia.com/patent/8058076
11. https://www.atccode.com/B03A
12. https://www.europarl.europa.eu/cmsdata/104729/EMA_annual%20report_without%20letter.pdf
13. https://patents.google.com/patent/US9376505B2/en
14. https://prediction.charite.de/subpages/tree.php
15. https://patents.google.com/patent/WO2021191926A1/en
16. https://go.drugbank.com/drugs/DB15598
17. https://patents.google.com/patent/US8025878B2/en
18. https://patents.google.com/patent/US8759320B2/en
19. https://www.lifearc.org/2017/lifearc-negotiates-exclusive-licence-deal-nemysis-limited-oral-iron-supplement-technology/